CARTESIAN THERAPEUTICS INC (RNAC) Stock Income Statement
NASDAQ:RNAC - Nasdaq - US8162123025 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 35.01M | 38.91M | 26.00M | 110.78M | 85.08M | |||
| Operating Expenses | 79.87M | 75.23M | 111.72M | 96.24M | 89.67M | |||
| Research and Development | 50.04M | 45.10M | 71.24M | 72.38M | 68.74M | |||
| Selling, General, and Administrative Expenses | 28.99M | 30.13M | 40.48M | 23.86M | 20.94M | |||
| Operating Income | -44.86M | -36.32M | -85.72M | 14.54M | -4.60M | |||
| Interest Income/Expense | 8.24M | 496.00K | -147.43M | -980.00K | -2.80M | |||
| Other Income/Expense | 6.18M | -33.74M | -4.86M | 21.21M | -2.32M | |||
| Non Recurring Items | N/A | -7.58M | -700.00K | 0.00 | 0.00 | |||
| Income Before Taxes | -38.02M | -77.14M | -238.71M | 34.77M | -9.72M | |||
| Income Tax | N/A | 287.00K | -19.00M | -609.00K | 15.97M | |||
| Net Income | -42.52M | -77.42M | -219.71M | 35.38M | -25.69M | |||
| EBITDA | -42.73M | -35.17M | -84.87M | 15.82M | -3.35M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.67 | -4.48 | -42.50 | 7.28 | -6.74 | |||
| Non GAAP EPS | -1.86 | -11.68 | -10.20 | 8.40 | -9.30 | |||
| Statistics | ||||||||
| Profit Margin | -121.45% | -198.97% | -844.91% | 31.94% | -30.19% | |||
| Operating Profit Margin | -128.14% | -93.33% | -329.63% | 13.12% | -5.40% | |||
All data in USD